【导读】券商资管披露旗下公募基金二季报 见习记者 舍梨 近日，公募基金二季报披露收官，券商资管的最新公募管理规模及基金经理观点也纷纷出炉。 从管理的公募资产规模来看，Wind数据显示，截至2025年二季度末，东方红资产管理（东证资管）、华泰证券资管、中银证券位居前三， 规模均超千亿元。此外，券商资管共有三位权益类基金经理的公募基金管理规模超百亿元，分别是东方红资产管理的李竞、周云以及中泰 资管的姜诚。 Wind数据显示，截至二季度末，共有4家券商资管机构的公募基金资产管理总规模超千亿元。东方红资产管理以1798.43亿元排名第一，华 泰证券资管以1651.11亿元排名第二，中银国际证券、财通证券资管分别以1303.12亿元、1136.07亿元排名第三、第四。 头部券商资管公募管理规模普遍增长 随后是国泰君安资管、招商证券资管、中泰证券资管，分列第五至第七，浙商证券资管、广发证券资管、银河金汇也居于前十。与一季度 末排名相比，广发证券上升一位，由第十名晋升为第九名。 例如，东方红资产管理医药基金经理江琦管理的东方红医疗升级股票发起A在今年上半年净值增长44.55%，创下成立三年多以来新高。 从持仓来看，截至今年 ...

Since the last time I wrote about immunology treatment provider AbbVie Inc. (NYSE: ABBV ) in April, its price hasn't moved much at all, with sub-2% gains. But short-term gains weren't the impetus behind the Buy rating on the stock anyway. It wasManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her inves ...

Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q3 2025 Outlook" report has been added to ResearchAndMarkets.com's offering.The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 18 significant catalyst events that are expected to occur in Q3 2025. Some of the catalysts covered in the report, include FDA app ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

Key Takeaways ALKS' alixorexton met primary goals in the phase II Vibrance-1 study for narcolepsy type 1. The 6 mg dose was the only one to meet a key secondary goal on cataplexy rates in the study. ALKS plans a global phase III trial as it eyes broader use of alixorexton in sleep disorders.Alkermes (ALKS) announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patien ...

Key Takeaways ABBV's neuroscience franchise is expected to generate $2.5 billion in Q2, up 15% year over year. Growth likely driven by Botox Therapeutic, Vraylar and market share gains for Qulipta and Ubrelvy. Newly launched Vyalev may contribute modest U.S. sales, with most revenues from international markets.AbbVie (ABBV) holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...

CVS Health (CVS) has been on a downward spiral lately with significant selling pressure. After declining 7.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscilla ...

Core Insights - Value investing focuses on identifying stocks trading below their intrinsic value, allowing investors to benefit as market prices align with true company value over time [1] - Earnings yield, calculated as earnings per share divided by stock price, is a useful metric for identifying undervalued stocks, with a higher yield indicating potential undervaluation [2][4] - A screening criterion of an earnings yield greater than 10% is established, alongside other parameters like estimated EPS growth and average daily volume [6][7] Company Highlights - IAMGOLD Corporation (IAG) is a gold exploration and mining company with projected earnings growth of 44% and 40% for 2025 and 2026, respectively, and currently holds a Zacks Rank 1 [9] - Plains GP Holdings (PAGP) is involved in crude oil and refined products transportation, with earnings growth estimates of 206% and 24% for 2025 and 2026, respectively, also holding a Zacks Rank 1 [10][11] - Hope Bancorp (HOPE) provides commercial banking services, with earnings growth estimates of 12% and 40% for 2025 and 2026, and holds a Zacks Rank 1 [12] - CommScope Holding Company, Inc. (COMM) offers communication network infrastructure solutions, with an extraordinary earnings growth estimate of 3,167% for 2025 and 28% for 2026, holding a Zacks Rank 2 [13] - Harmony Biosciences Holdings Inc. (HRMY) focuses on therapies for rare neurological disorders, with earnings growth estimates of 22% and 32% for 2025 and 2026, and holds a Zacks Rank 2 [14]

Core Insights - The Price-to-Book (P/B) ratio is a valuation metric that compares a company's market capitalization to its book value, helping investors identify undervalued stocks with strong fundamentals [1][2][6] - The P/B ratio is particularly useful in value investing, where investors seek stocks that are cheap yet fundamentally strong [1][10] - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued, while a ratio above one may indicate overvaluation [6][8] Understanding Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities [4][5] - It is calculated by subtracting total liabilities from total assets, often equating to common stockholders' equity [5] P/B Ratio Analysis - The P/B ratio is calculated as market capitalization divided by book value of equity, providing insight into whether a stock is under- or overvalued [2][6] - Stocks with low P/B ratios and strong projected earnings growth are considered attractive investment opportunities [10][16] Screening Parameters for Investment - Stocks should have a P/B ratio lower than the industry median, a P/S ratio below the industry average, and a P/E ratio using F(1) estimates that is also lower than the industry median [12][13] - A PEG ratio of less than 1 indicates that a stock is undervalued relative to its growth prospects, while a minimum trading price of $5 and a substantial average trading volume are also recommended [14][15] Notable Stocks with Low P/B Ratios - CVS Health (CVS) has a projected 3-5 year EPS growth rate of 11.4% and holds a Zacks Rank of 2 with a Value Score of A [16] - Signet Jewelers (SIG) has a projected EPS growth rate of 12.2% and also holds a Zacks Rank of 2 with a Value Score of A [17] - KB Financial Group (KB) has a projected EPS growth rate of 12.33% and a Zacks Rank of 2 with a Value Score of B [18] - Affiliated Managers Group (AMG) has a projected EPS growth rate of 14.2% and a Zacks Rank of 2 with a Value Score of A [19] - PagSeguro Digital (PAGS) has a projected EPS growth rate of 11.3% and holds a Zacks Rank of 1 with a Value Score of A [21]

AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about tariffs loom over the industry. https://t.co/MYmPLMR2Jq ...